Alzamend Neuro, Inc. (ALZN)
1.68
+0.02
(+1.20%)
USD |
NASDAQ |
Sep 08, 16:00
Alzamend Neuro Price to Book Value : 9.752 for Sept. 8, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 9.752 |
| September 04, 2026 | 9.636 |
| September 03, 2026 | 9.868 |
| September 02, 2026 | 9.868 |
| September 01, 2026 | 9.501 |
| August 31, 2026 | 9.288 |
| August 28, 2026 | 9.636 |
| August 27, 2026 | 9.665 |
| August 26, 2026 | 9.694 |
| August 25, 2026 | 9.288 |
| August 24, 2026 | 8.997 |
| August 21, 2026 | 9.055 |
| August 20, 2026 | 9.462 |
| August 19, 2026 | 8.823 |
| August 18, 2026 | 8.823 |
| August 17, 2026 | 9.171 |
| August 14, 2026 | 8.997 |
| August 13, 2026 | 8.475 |
| August 12, 2026 | 8.359 |
| August 11, 2026 | 8.533 |
| August 10, 2026 | 8.475 |
| August 07, 2026 | 7.952 |
| August 06, 2026 | 8.010 |
| August 05, 2026 | 8.301 |
| August 04, 2026 | 8.417 |
| Date | Value |
|---|---|
| August 03, 2026 | 7.778 |
| July 31, 2026 | 7.604 |
| July 30, 2026 | 7.836 |
| July 29, 2026 | 7.778 |
| July 28, 2026 | 7.604 |
| July 27, 2026 | 7.778 |
| July 24, 2026 | 7.720 |
| July 23, 2026 | 7.314 |
| July 22, 2026 | 7.836 |
| July 21, 2026 | 7.662 |
| July 20, 2026 | 7.314 |
| July 17, 2026 | 7.024 |
| July 16, 2026 | 7.082 |
| July 15, 2026 | 7.140 |
| July 14, 2026 | 7.024 |
| July 13, 2026 | 6.733 |
| July 10, 2026 | 6.850 |
| July 09, 2026 | 6.733 |
| July 08, 2026 | 6.675 |
| July 07, 2026 | 6.617 |
| July 06, 2026 | 6.733 |
| July 02, 2026 | 6.733 |
| July 01, 2026 | 6.501 |
| June 30, 2026 | 6.966 |
| June 29, 2026 | 6.733 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.660 |
| Alnylam Pharmaceuticals, Inc. | 25.59 |
| Anika Therapeutics, Inc. | 2.071 |
| Savara, Inc. | 7.807 |
| Vericel Corp. | 5.379 |
Price to Book Value Related Metrics
| Price | 1.68 |
| Earnings Yield | -172.4% |
| Market Cap | 7.150M |